I reckon it is just EOFY dumping. However, there are two differences between the January FDA approval and this one. First (sorry to rehash what has already been said), no comments on the nature of the settlement agreement with Jublia's patent holder vs the declared plan with the patent holder in Jan. and second: January amounts to a small contract - steady income but no multi-bagger.
Hoping for a healthy price jump by Thursday...
Add to My Watchlist
What is My Watchlist?
